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INTRODUCTION

During the last few years * the interests of the
surgeon and the immunologist have been focused on the
remarkable immuno-suppressive powers of antilymphocyte
serum.

Such serum has come into use in experimental and

clinical organ transplantation in many series.

We shall

here discuss what is currently known about its specificity
and mode of action.
The work of several early investigators with anti¬
leucocyte sera has been well summarized by Russell and
Monaco (31).

In 1937* Chew and Lawrence (6) demonstrated

that a serum raised in rabbits against guinea pig lymph
node cells produced a fall in total lymphocyte counts when
administered to guinea pigs* and that daily Injections
could maintain lymphopenia up to ten days.
counts were depressed from a level of

Lymphocyte

^-5*000 to 1*000 or

less* but Increasing doses could not totally ablate peri¬
pheral lymphocytes.

They found a generalized hyperplasia

of lymphoid tissue* which was also seen after injections
of normal rabbit serum.

In 19^1* Cruickshank (7) demonstra¬

ted lymphopenia in rats given rabbit anti-rat lymphocyte
serum* and showed that incubation of such serum with rat
lymphocytes utilized complement.

He also noted lymph node

hyperplasia.
In 1956* Interbitzin (12) demonstrated that antilympho¬
cyte serum inhibits tuberculin sensitivity in rats.
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Wilhelm et al., in 1958.,

(36) noted that administration

to guinea pigs of rabbit anti-"mononuclear"

serum induced

a depletion of circulating mononuclear cells., which was
correlated with a marked reduction in allergic contact
sensitivity*

The growing awareness of the role of lympho¬

cytes in depayed hypersens itivity, and, specifically,
allograft rejection, led Woodruff (37) to investigate the
effects of antilymphocyte serum on allografts of skin and
endocrine tissue in rats*

These experiments were unsuccess¬

ful, but Woodruff has recently admitted (40) that the sera
used were not sufficiently potent and the doses too small.
In 1961, Waksman et al.

(35) reported definite reduction

in a variety of reactions of the delayed type after treat¬
ing guinea pigs with rabbit anti-guinea pig lymphocyte serum.
A slight, but definite, prolongation of first set allografts
was notedj there was also some histological evidence of
slightly delayed rejection

of second-set grafts.

Repeated

injections of the antiserum over several days produced
lymphopenia which became less marked with continued treat¬
ment.

Clear-cut depletion of small lymphocytes in lymph

nodes was noted,
McGregor and Gowans (27, 28) showed that chronic
depletion of rat small lymphocytes by a thoracic duct
fistula led to a marked reduction in various Immorally
mediated immunologic responses, as well as a definite
prolongation of first set allografts.

They were unable to

affect secondary humoral responses or second set grafts.
They could not conclude, however, that lymphocytes are not
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involved, in the latter reactions,in view of a personal
communication from Mithchell and Gowans that a typical
secondary response followed the first challenge of rats
with diphtheria toxoid occurred, if these rats has previ¬
ously been given lymphocytes from other, primarily sensi¬
tised rats.
Woodruff and Anderson (38, 39) were the first to
demonstrate marked prolongation of skin graft survival
with antilymphocyte serum; they used a rabbit anti-rat
lymphocyte serum, and showed prolonged survival even when
distantly related rats were used as donor and recipient.
They reported that the lymphocyte count tended to rise
during the course of serum treatment.

Sacks et al,

(32)

showed that, in rats given rabbit anti-rat lymphocyte serum,
the degree of lymphopenia at 2h hours was dose dependent;
furthermore, the lymphopenic effect persisted on long-term
treatment.

To explain this effect, they suggested, but did

not document, that their serum was able to suppress anti¬
body formation against itself.

Hemagglutinins and hemo¬

lysins present in the serum could be absorbed without
interfering with the lymphopenic effect.

This has been a

consistent observation in reports,from other laboratories.
Sacks et al., in the same article, reported geldiffusion studies that demonstrate precipitin activity of
their antilymphocyte serum against a variety of rat tissue
homogenates.

Precipitin bands were formed against lymphoid

tissue, kidney, liver, and (weakly)

muscle,

A spur was

seen on the middle lymph node band that went beyond the
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joining kidney band.

Two bands were seen with the lymph

node homogenate that were not present against other tissues.
These data were interpreted to suggest that lymphoid tissue
may contain antigens not present on other tissues,
Nagaya and Sieker (29) showed that an antiserum to
thymus cells was more effective, as measured by lympho¬
penia and allograft survival, than antiserum to mesenteric
lymph node cells.

The results previously observed in rats

have been reproduced in mice by Gray et al.
et al,

(26), and Levey and Medawar (20,21).

(10), Monaco
These groups

demonstrated prolongation of second-set as well as firstset skin grafts.
James (15) has reviewed many current studies demonstra¬
ting usefulness of antilymphocyte antibody in protecting
renal transplants against rejection, as well as its effect
on humoral antibody formation and other immune phenomena.
Whole serum and globulin fractions have been immunosuppres¬
sive in just about all systems studied, except, notably,
formation of secondary humoral antibody (e.g. Monaco et al,,
26).
Gray, et al.

(10) reported that blood taken from mice

one week after the last of 9 injections, over two weeks, of

.25 c.c. of rabbit anti-mouse lymphocyte serum, contained
little or no activity against rabbit gamma globulin, as
compared to high titers in mice given equivalent doses of
normal rabbit serum.

The control was thought to rule out

immunological paralysis as a mechanism, and the authors
interpreted the result as showing specific immune suppression.
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by their serum* of antibody formation against itself.

Lance

and Dresser (19), however* showed* in a very elegant experi¬
ment studying disappearance rates of isotopically labelled
globulins* that antilymphocyte serum could be immunogenic
in doses producing potent immunosuppression.

In fact*

it seemed to be more immunogenic than normal serum.

Their

data were interpreted to suggest that unresponsiveness in
mice to rabbit serum* after prolonged periods of exposure
to rabbit anti-mouse lymphocyte serum* may actually repre¬
sent immunological paralysis.

The key point* in order for

antilymphocyte serum to maintain unresponsiveness against
itself would seem to us to be the use of it in high doses
continually;
protocols,

this conclusion is consistent with both
Lance and Dresser*s protocol shows immuno¬

genic ity of antilymphocyte serum* as measured by rapid
elimination of a dose of normal rabbit serum administered
several weeks after the injections of antilymphocyte serum;
in contrast*

Monaco’s observation is that a single, inten¬

sive course of a potent serum can fail to produce measureable anti-globulin activity when there is no subsequent
challenge.

Indeed* In a more recent paper* Russell and

Monaco (31) have shown that a small injection of their
serum* followed several months later by a second injection,
will indeed incite formation of anti-globulin.
Starzl et al.

(3*0 have recently shown that human

renal allograft recipients treated with anti-lymphocyte
serum in their series developed significant precipitin
titers against ALS* and that this reaction could be
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attenuated by simultaneous use of steroids.

Their data

also suggest that a spontaneous decline in late host
reaction to foreign protein may occur during serum treat¬
ment.

It is not clear from his data whether this phenomenon

represents specific ALS-inauced immunosuppression of
reaction against itself, or a less specific immune paralysis
James (15) has reviewed other studies which show In
recipients of antilymphocyte serum, either antibodies
against donor globulin, rapid "immune" elimination of
anti-lymphocyte IgG, or "immune complexes" in transplanted
organs.

Monaco’s serum seems to be among the strongest

of those reported so far, at least as measured by persis¬
tence of lymphopenia, and suppression of reaction against
itself.

Perhaps the clinical lesson is that very strong

sera or fractions must be produced if ALS is to enjoy
clinical usefulness, and,again, that it must be used

in

high doses without interruption if used at all.
Much has been written about the specificity and mode
of action of anti-lymphocyte serum.

The obvious assump¬

tion from early experiments might be that the serum acts
specifically on lymphocytes, and t,hat the mechanism is
cell lysis.

Recent reports have called into question both

of these ideas, however.

We shall here attempt to review

current studies relating to these two questions.

It is

difficult to make a complete distinction between specificity
and mode of action;
questions.

some objections pertain to both

We shall treat the questions separately, however

even though the discussions will overlap somev.liat.
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page 7
G-ray, et al,

(10) feel that their serum acts primarily

by specific immune lysis of lymphocytes, both central and
peripheral.

Their serum had strong agglutinating and

cytotoxic activity against, mouse lymph node cells of
several strains, as well as precipitin activity in gel
diffusion against mouse lymph nodes, spleen, liver, kidney,
i

and muscle: homogenates.
diffusion study,

As with Sacks’s (32) earlier gel

serum diffusing against spleen and lymph

node homogenates produced some lines which were not present
against other tissues.

In addition, these authors showed

that absorption with mouse liver and kidney removed precipi¬
tin lines against these tissues, but left unaltered the
precipitin line against spleen and lymph nodes.

In contrast,

absorption with spleen or lymph node cells removed
precipitin lines against all tissues.

Cytotoxic, activity

of their serum against lymph node cells could also be
markedly reduced by absorption with spleen or lymph node
cells, but not with liver or kidney cells.

The same effects

were noted (but data not presented) on lymphagglutinin
titers.

Finally, absorption with lymphoid cells could

remove the lymphopenic effect of a diluted sample of serum,
whereas absorption with liver cells could not remove this
effect.

The authors concluded that their serum contained

antibodies directed against antigens specific to lymph node
cells.

Not all their data are conclusive, however, for

several reasons.

First, the absorptions in their lympho¬

penia experiment do not seem to have been complete with
lymphocytes, nor to have been totally ineffective with liver
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cells, at

least as measured by absolute lymphocyte levels

after treatment; in addition, it seems they only used one
animal for each serum tested.

Second, they did not titrate

cytotoxic antibody, but rather measured the effects of
undiluted sera alone.

The maximum percent dead cells in

their cytotoxic experiment was 55$.

Our experiments have

shown that meaningful data with cytotoxicity (at least
against myeloma cells) require titration with serial
dilutions, and that the lowest dilutions with antiserum
characteristically show 98-100$ cytotoxicity against the
cell the serum was raised with.

Thus it seems difficult

to interpret some of the data of Gray, et al«, with the
same enthusiasm as the authors do.

Nevertheless, the

profound and persistent lymphopenia they achieved, as well
as their gel-diffusion and lymphagglutinin results, strongly
support their conclusions.
group,

In a later report, the same

(31) has shown a picture of a frozen section of a

human kidney, which they exposed to rabbit antihuman lympho¬
cyte serum, washed, and covered with fluorescein-labelled
goat anti-rabbit gamma globulin antibody;

selective

adherence of the ALS to lymphocytes in capillary tufts is
clearly demonstrated.

This adds much weight to their conten¬

tion that immunization with lymphocytes can induce cellspecific antisera.
Woodruff and Anderson (40) noted uptake of antilympho¬
cyte antibody, using a similar fluorescent technique, by
in vitro suspensions of thoracic duct lymphocytes.
report, they did not give data on similar tests with
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non-lymphoid cells, but they gave evidence that their
rabbit anti-rat ALS

had an insignificant cytotoxic titer

against peritoneal macrophages of the rat, as opposed to a
high titer against rat lymphocytes.
Evidence has been presented, however, that antilympho¬
cyte serum is not specific in any histological sense.
Levey and Medawar (20) have shown that sera prepared in
rabbits against mouse L cells and mouse basal epidermal
cells exerted a significant prolongation on murine skin
allograft survival.

None of their sera here was prepared

according to the protocol they used for all their antithymic serum.

A serum prepared with a number

of L cells

5 times the usual number of thymocytes used, with the
same protocol of rabbit injections and bleeding, prolonged
the mean survival time

(MST) of allografts 3*7 days beyond

the MST of control allografts, and prolonged none by more
than 5.4 days,

Antithymic serum administered in the same

way, as reported in a different paper (21), prolonged
survival of all grafts at least 8.5 days, half the grafts
by 18 days, and two (of twenty) by 38 and 52 days, respec¬
tively.

Their two strongest anti-epidermal sera prolonged

the MST by 12.1 and 6,6 days, and no grafts were prolonged
by more than 17.^ and 9*^ days, respectively.

Fewer cells

were used in each injection, but the active sera were
harvested after four and five injections, respectively,
whereas all their antithymic sera were harvested after
two injections.

Thus it is impossible to quantitate the

difference among the effects of their sera, although
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clearly antithymic serum had the most profound effect.

It

is unfortunate that the authors did not describe the effects
of their anti-epidermal and anti-cell sera on peripheral
lymphocytes.

Nevertheless, the prolongation exerted by

these sera on allograft survival is significant, and the
authors’ contention that ALS is not specific in the histo¬
logical sense has considerable

merit.

We shall discuss

the point below, in reference to our own experiments.
The antithymus serum of Levey and Medawar (21) had
little lymphopenia effect at four hours, after a single
injection, but the lymphocyte counts apparently fell further
and were recorded at 7 and 1*1 days as roughly 60-70$ of the
original level.

Although Gray et al.

(10) reported a

substantial fall In lymphocyte counts at four hours, the
percent of original lymphocytes remaining at ten days was
not significantly different in their study from that
attained by Levey and Medawar.
Several investigators have reported that, during treat¬
ment of rats with ALS, lymphocyte depression was not always
maintained during prolonged allograft survival (Woodruff and
Anderson, 38;

Nagaya and Sieker, 30; Anderson, James, and

Woodruff, lj Sacks, et al., 32),

Certainly these observations

might cast doubt on the specificity of ALS for lymphocytes,
or, alternatively, they might call into question the cyto¬
toxic theory of action of ALS (which is discussed below).
Indeed, Levey and Medawar have implied (20) that return of
peripheral lymphocytes towards normal levels may be irrele¬
vant or even desirable.

Interpretations of these data as
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disproving specificity of ALS for lymphocytes could be
overcome if it could be shown that the return of lympho¬
cytes towards normal during treatment represents a compen¬
satory increase of a sub-population of unsensitized cells,
or cells that cannot be sensitized (Levey and Medawar’s
"sterile activation" theory, discussed below).

Similar

confusion about lymphocyte levels exists in canine trans¬
plantation experiments; again, Monaco’s group (25) noted
persisting lymphopenia, using material prepared with
adjuvant, while Starzl’s group (33) reported inconsistent
lymphopenia.
Aside from the issue of the actual specificity of ALS,
there are several different theories as to its mode of
action.

These theories have been reviewed in detail by

Levey and Medawar (21, 23),
James (15).

Bussell and Monaco (31), and

The most prominent are the cytotoxic, blind¬

folding, competitive antigen, and sterile activation
theories.
The first and most obvious theory is that ALS acts
essentially as a lymphocyte depleting, or cytotoxic, agent.
We have seen that Gray, Monaco, and Russell have strongly
advocated this theory.

We have cited several papers which

show that with some sera lymphopenia need not be marked or
sustained during periods of immunosuppression ( a fact which
is also relevant to the question of specificity),

Levey

and Medawar (21) have maintained that "the lesser immuno¬
suppressive action" of the thoracic duct drainage experi¬
ments of McGregor and

Gowans (27, 28), which produced "a

■
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greater lymphocyte depletion

[than is observed with ALSj

argues against the cytotoxic theory,

McGregor and Gowans

observed that thoracic duct drainage significantly prolonged
survival of first-set grafts in their non-inbred rats,

A

much lesser but significant effect was recorded in "distantly
related" animals.

The authors were unable to prolong

second-set grafts, when the course of depletion was begun
immediately after first-set rejection,

Levey and Medawar

(21) got a significant prolongation of second-set graft
survival in mice with their antithymic serum, but they
began the experiment 1-4 days after first-set graft rejection,
when presumably there may have been more of a decline in
quantity and quality of sensitization, or when "memory
cells" may have moved from lymph nodes into the more access¬
ible circulation.

It seems Levey and Medawar’s arguments

cannot be accepted until experiments are reported in a
single species with' parallel courses of thoracic duct
drainage and anti-lymphocyte serum administration.

Woodruff

and Anderson (38, 39) have reported a synergistic effect
on rat allograft survival of ALS treatment and thoracic
duct drainage.

They did not do parallel studies isolating

the two techniques, however.

Examination of their graphs

reveals that a seven day course of ALS (prior to grafting)
had a more profound lymphopenic effect than thoracic duct
drainage done over five days.
An impressive series of experiments has recently come
out of Woodruff’s laboratory on the immunosuppressive
properties of various fractions of ALS XgG,

James (15) has
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interpreted the failure of the non-cytotoxic f(ab*)p
antibody fragment to produce immunosuppression (l, 1^, 16)
as favoring the cytotoxic theory*

This conclusion, of

course, assumes that in vitro cytotoxicity and in vivo
cell lysis are equivalent phenomena.
Perhaps selective destruction of a sub-population of
lymphocytes in a state of readiness to undertake immune
responses, and with proportional sensitivity to antilympho¬
cyte serum, is the mechanism (20, 16), and failure to
achieve gross depletion of the lymphocyte population need
not in itself nullify the cytotoxic theory (l4).
There are several other theories, based on coating of
lymphoid cells by antilymphocyte serum without lysis.
These are the blindfolding, the competitive antigen, and
the sterile activation theories; they tend to overlap
somewhat,
Levey and Medawar (22) showed that lymphocytes from
CBA mice that had previously rejected skin from C57 mice
could lyse C57 fibroblast monolayers in vitro, and that such
lysis could be inhibited by prior incubation of the lympho¬
cytes with heterologous antilymphocyte serum.

"Blindfold¬

ing" of lymphocyte combining sites or recognition units
might then, they proposed, explain the in vivo mechanism
independent of cytotoxicity.

In further work, however,

(20) this group found that cells from serum treated donors
failed to restore immunological competence to previously
irradiated recipients, even though these cells presumably
must have undergone several generations of division, and
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lost their antibody coat.

Russell and Monaco (31) have

recently cited unpublished observations by Dr. B. van der Werf
in their laboratory* showing that lymphoid cells from ALS
treated animals failed to produce the usual graft versus
host reaction in newborn recipients* tending to confirm the
previous experiment in disproving the blindfolding theory.
Russell and Monaco concluded that the population of cells
remaining in lymph nodes after serum treatment was definitely
incompetent - either from some form of selective destruction
of competent cells* or because of converstion of competent
cells to an incompetent form.
course*

The latter suggestion, of

is a departure from their previous cytotoxic theories.

Guttman et al.

(ll) have recently suggested a variant

of the blindfolding theory* that the antibody coats the
graft tissue* which shares antigens with lymphoid tissue*
thus preventing histocompatibility antigen release, or
recognition by the lymphocyte of such antigen ( a mechanism
similar to immunological enhancement).
strated that prior treatment of

The authors demon¬

hybrid rat donors with

an antithymic serum leads to a definite uptake of globulin
in donor kidney tissue* and that transplantation of kidneys
from these animals into parent strain untreated recipients
led to definite slowing of rejection.

Perhaps Levey and

Medawar’s anti-epidermal serum (20) might work in part
through this mechanism in prolonging survival of allografts
of skin.

We have seen how Sacks et al., and Gray* et al.,

have shown by gel diffusion that their rabbit anti-rat
lymphocyte sera cross-react with a number of tissues, but
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that there are probably specific lymphocyte antigens not
shared by other tissues.

Iwasaki et al.

(13) have main¬

tained that multiple absorptions of their anti-dog lympho¬
cyte serum with liver and kidney cells absorbed out 90% of
the agglutinating activity of the serum.

They concluded that

most of the antigens of the lymphocyte in the dog are
represented in other tissues.

They failed to show whether

there are any lymphocytes in dog kidney and liver parenchyma.
The only data they show indicate that a single exposure of
their serum to kidney or liver reduces the leukoagglutinin
titer from 1:4096 to 1:1024, and this is termed a 75^
reduction in titer.

They did not test the leukoagglutinin

titer of normal horse serum, which is presumably negligible,
nor did they test the titer of immune serum absorbed with
identical quantities of lymphoid tissue.

It is tempting

to conclude from these data nevertheless, that most of
the antigens on lymphoid tissue are represented on other
tissues.

However, other data, in the same report, show

that absorption of their serum with liver and kidney did
not alter its lymphopenic effect.
Cerilli, et al.

(5) have recently repeated Guttman’s

experiment on the treatment of the donor of a kidney with
antilymphocyte serum before transplantation, to test the
graft-blindfolding hypothesis.

Cerilli et al. used dogs

instead of rats, and prepared their serum in horses.

No

effect on graft survival was noted, in contrast to Guttman's
findings with inbred rats.

The conclusion was that the

immunosuppressive effect at the graft site is probably
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small, and only noticeable in an inbred animal system.
Certainly experiments must be done using sera prepared
against tissues other than lymphoid organs in dogs to
clarify this point.

We have not seen reports, in any

system, on the effect of absorption by other organs on
in vivo immunosuppressive action of antilymphocyte serum.
The "competitive antigen" theory, in many ways similar
to

the blindfolding theory, differs in involving a

specific and preferential immunological commitment of
lymphocytes to anti-lymphocyte antibodies acting as anti¬
gens (15).

This theory is perhaps supported by the work

we have quoted showing that, under proper conditions,
antibody to ALS or normal IgG from the species donating
the serum may be noted in recipients.

James (15) discusses

the point further.
The theory of "sterile activation"
by Levey and Medawar (20).

has been proposed

The theory is based on their

observations, and those of other,

(6,7) that lymphoid

hyperplasia and the formation of blast cells occurs in
lymphoid organs with certain sera and protocols,

(in

,

contrast. Gray, et al. 10, and Waksman et al,, 35
ed depletion in their studies.

report¬

Although Monaco and Russell's

group have consistently seen lymph node depletion in all their
experiments, they have recently reported (31) "large, foamy
lymphoid cells In the periphery similar to many of those
left in lymphoid tissue.")

Levey proposed that antilympho¬

cyte sera may at least in part act through a sterile acti¬
vation of lymphoid cell size and growth rates, forestalling

.
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all other Immunological commitments.

Grasbeck (9) showed

earlier that rabbit anti-human lymphocyte serum can
activate in vitro human lymphocytes mitoticaily.
et al.

Woodruff

(4l, 42) have recently shown that horse anti-human

lymphocyte IgG can stimulate the uptake of Isotopically
labelled nucleosides into lymphocyte nucleic acid.
et al.

Ling

(24) have done a similar experiment, and they showed

that there is not a constant correlation between trans¬
forming antibodies and either cytotoxic or agglutinating
antibodies,
There are two major obstacles to the immunosuppressive
relevance of blast transformation and its in vivo equiva¬
lent, sterile activation.

First stand the observations

of Woodruff et al. that the same effect is achieved by
the divalent f(ab1)

IgG fraction (4l); this fraction is

non cytotoxic, and has no effect on immune responses, at
least in rats (l, 14).

Second, complement must be excluded

from all in vitro systems using whole immune serum or
intact IgG, to get blast transformation; otherwise, lysis
occurs (9*24).

It is not unreasonable to assume that

recipient complement has access to sites
heterologous antilymphocyte serum.

of action of

It would seem that the

crucial experiment to determine the immunosuppressive
significance of in vitro blast transformation would be
to test whether antibody treatment, without complement,
can depress immunologic responses of lymphocytes in culture
To our knowledge, no such experiment has been published;
until it is, the role of sterile activation in ALS-induced
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immunosuppression seems to be in doubt.
Many questions about the specificity and mode of
action of antilymphocyte serum are obviously unanswered.
Questions about its method of action are certainly of more
than academic interest, especially in respect to the
rationale for selecting appropriate tests for assaying
potency of serum batches.

Cytotoxicity in vitro, lympho¬

penia in vivo, lymphagglutination, or in vitro blast
transformation are all possibilities, but it is not yet
known which is the best test.
It would seem that the more pressing practical
question,however, concerns the specificity of the serum.
It seems clear from many papers we have considered, that
there are many antigenic determinants on the lymphocyte
of all species studied,

A key question, as yet not fully

answered, is whether there are any antigens peculiar to
the lymphocyte.

The gel diffusion studies of Gray et al,

(10), as well as those of Sacks et al.

(32), indicate

there may indeed be specific groups on lymphocytes,
Iwasaki*s serum (13) induced lymphopenia after liver and
kidney absorption, but there are other data in his paper
in conflict with this observation.

Certainly Levey and

Medawar (20) attained immunosuppression with anti-epider¬
mal, and to a far lesser extent, with anti-L cell serum,
Levey refers (23)

to unpublished work of S.V. Joost that

rabbit anti-mouse fibroblast serum has a similar effect.
But in all of these observations of Levey and Medawar,
the immunosuppression achieved by such sera had- a much

.t

,
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lesser effect than their own antithymic serum..
It would seem consistent with most reported results
that there may be some lymphoid-specific antigens.

At any

rate, a most important consideration, consistent with most
available data, is the possibility that circulating
lymphoid tissue is a highly vulnerable target, much more
so than any solid tissues, for reasons of either structural
weakness, high concentration of antigen (either cell or
species specific), or just general physical availability.
For any of these reasons, antibodies raised against lympho¬
cytes might be expected to act more quickly and/or effec¬
tively against lymphocytes than against tissues not
involved in the immune response, even if non-lymphoid
tissues should possess potential binding sites.
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PURPOSE OF THE EXPERIMENT
While working as a research assistant in the labora¬
tory of Drs. Paul S. Russell and Anthony P, Monaco in the
summer of 1966, the author became intrigued with the possi
bilities for use of antilymphocyte serum in clinical
transplantation work.

Access at that time to a draft of

work later published by Levey and Medawar (20) raised
many doubts about the specificity of such sera for lympho¬
cytes.

Accordingly, it was thought appropriate to raise

a serum against a pure cell line, in the mouse, of nonlymphocytic and non-graft origin, and then to attempt to
elicit and characterize any activity of this serum against
lymphocytes in vitro and in vivo, comparing this activity
with any effect this serum might have on the allograft
response.
We selected murine myeloma cells as an appropriate
cell line;

we received a specimen of the transplantable

C3H myeloma X5563* and have maintained this tumor in
subcutaneous form in this laboratory.

Histology of this

tumor reveals a rather well differentiated cell population
resembling closely the appearance of normal plasma cells.

MATERIALS AND METHODS
Animals
White New Zealand female rabbits (about 2.5-3*0 kg,)

.

•
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were used to prepare all antisera.

Inbred adult female

mice of the C3H/HeJ strain were used to carry the tumor,
and as recipients of all sera and skin grafts.
female Balb/c mice were used as graft donors.

Adult
All mice

were obtained from Jackson Laboratories in Bar Harbor, Maine
and were not bred in this laboratory.
Preparation of Myeloma Cells for Immunization
It was found convenient to maintain the turner in
subcutaneous form.

About ten days to two weeks after

injection of cells into C3H mice under flank skin,, a large,
firm mass becomes evident.

On exposure, these tissue

masses are usually white and smooth, with moderate vascu¬
larization.

For purposes of immunization, tumor cells

were pressed through a wire screen by a garlic press into
Hank's medium, under sterile conditions, to separate the
cells.

The method of Gordon et al,

(8) was employed to

separate out non-myeloma elements (this method was origin¬
ally described for use with ascites forms of X5563 myeloma,
but was found adequate for solid subcutaneous tumors here).
Cell suspensions were centrifuged at 600 RPM in a 2A0 head
for 3 minutes, after which all supernatent, and, when
necessary, red cell rings, were removed by aspiration.
When this procedure had been repeated 10 times, a prepara¬
tion of 99% myeloma cells was attained.
Preparation of Anti-Myeloma Serum
The protocol of Gray et al.

(10) was followed.

appropriate number of cells was suspended in Hank's

An
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medium, and emulsified with an equal volume of complete
Freund’s adjuvant.

Several rabbits received 0.2 ml of

the emulsion into each foot-pad, to give a total of
100xl0u

cells per rabbit.

Booster injections of cell

suspensions {100x10^ cells again)

in Hank’s medium were

given to each rabbit through an ear vein on three successive
days 4 weeks later.

The rabbits were bled by cardiac

puncture 7 days after the last injection, and on one or
two subsequent days in those who survived the first massive
bleeding.

All blood samples were allowed to clot and

stand in the cold (4° C) overnight.

Some tubes of immune

and normal serum showed evidence of gross hemolysis after
clotting.

All sera were separated from the clots and

pooled, diluting out to unnoticeable color any hemoglobin
contamination.

All sera were immediately heated to 56° C

for 30 minutes, and stored at -20° C until use.

No signi¬

ficant hemaggluttination activity was found in either the
immune or normal pools, and no red cell absorptions were
carried out.
A sample of rabbit anti mouse (A/Jax strain) lympho¬
cyte serum, prepared by the same protocol, was kindly
donated by Dr. Anthony P. Monaco.
Cytotoxic Antibody Assay
a.)

Preparation of Cells

Myeloma cells were harvested from a subcutaneous tumor
masses in a manner similar to that described above, but
sterile technique was not rigidly observed, and the tumor
cells were treated with extra care so as not to damage
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cells.

Tumor masses were cut to small size with two

Bard-Parker #11. scalpel blades, then teased gently to
release cells.

The suspensions were then either poured

through a wire mesh, or through a piece of cotton gauze,
to filter out large particles.

The cell suspension was

allowed to stand for 15 minutes at room temperature to
allow smaller clumps to settle, whereupon the supernatant
was poured off and used as a source of viable myeloma cells.
There was moderate red cell contamination, of course, but
it was not felt necessary to separate the two cell popu¬
lations by centrifugation;

indeed, this probably would

have caused unnecessary damage of tumor cells,
b.)

Cytotoxic Test Procedure

A simplified test described by Boyse et ah,
used by Gray et al,
success.

(3) and

(10), was repeatedly attempted without

This method consists of adding cell suspensions,

serum dilutions, and complement directly into vaseline
rings on ordinary slides, incubating at 37°, and reading
directly the per cent dead (stained) cells.

Perhaps our

source of lyophilized guinea pig complement was inactive.
At any rate, it was found that the vaseline rings tended
to melt on the microscope from the heat of the lamp, and
frequently all the cells clumped against the vaseline ring.
We rarely saw saw a dead cell, and the "simplified” test
seemed very unwieldy anyway, so we discarded it, along
with the reconstituted lyophilized complement.
Eventually, with the assistance of Dr. Kikuo Nomoto,
we achieved significant and reproduceable results using a
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modification of a cytotoxic technique described later by
Boyse, et.al.

(4)

All incubations were done in clean, dry

small test tubes.

To each tube was added .25 c.c. of

doubling dilutions of serum to be tested, whereupon 0,1 c.c.
containing 10^ cells was immediately added to each tube.
The mixture was allowed to stand at room temperature for
15 minutes to allow fixation of antibodies.

Then, to each

tube was added 0,1 c.c. of a 1:5 dilution of freshly prepar¬
ed (within 1 week) guinea pig serum as a source of comple¬
ment.

Tubes were then incubated at 37° for 30 minutes.

Immediately before reading each tube, 0.1 c.c. of freshly
prepared 0.2$ trypan blue was added, and the tube was
then gently shaken,

A drop of the cell suspension was

then placed in a standard white cell counting chamber, and
the per cent dead cells (blue stained) was determined.

All

tubes that were not going to be read soon, when a lot of
tubes were to be counted, were put at 4° until about ten
minutes before reading.

Tubes were read in parallel, i,e»,

all the tubes of the same dilution,
tubes, were read together,

to

from each series of

eliminate bias due to any

cell death while tubes were waiting to be read.

All results

of cytotoxic antibody determinations have been expressed
as titration curves of percent dead cells vs, dilution of
antiserum used.

Controls in every experiment included per

cent dead cells in initial sample (diluted in Hank's only,
and not incubated), as well as two incubated complement
controls, read at the beginning and at the end of all read¬
ings, respectively.

Normal rabbit serum had no activity
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against any cell tested, and it was not felt necessary
to titrate it every time a cytotoxic assay was done after
the first couple of times.

All dilutions were done in

Hank's medium with 2% by volume normal rabbit serum,
Absorptions_
a, )

Cell Suspensions

Sterile cell suspensions were prepared as described
above, with both lymphocytes and myeloma cells.

Packed

cells were mixed with antiserum, 5$ cells by volume,
suspended, and left overnight.

Cells were gently spun

down and the procedure was repeated for a total of three
times,
b. )

Serum Absorptions

An experiment was designed to determine the minimum
quantity of C3H serum needed to absorb out all anti-C3H
serum protein (or, perhaps, anti-myeloma-produced globulin}
activity, from the immune serum.

To successive tubes

containing 0.5 c.c, of anti-myeloma serum were added
aliquots of C3H serum, either straight or diluted represent¬
ing 0,3 c.c down to 0,01 c.c.

After the tubes had stood

overnight, a precipitate was visible in all tubes, and
addition of more C3H serum to the supernate of all tubes
produced no more precipitate.

Accordingly it was judged

that 2% by volume of C3H serum was adequate to absorb anti¬
serum protein activity out of anti-myeloma serum, and this
was done with a large amount of the serum.
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In Vivo Effect on Circulating Lymphocytes
A series of 8 mice was injected with various sera
according to the protocol elaborated below, to assay the
lymphopenic effects of our anti-myeloma serum, normal
rabbit serum, and Dr. Monacofs anti-lymphocyte serum.

All

blood samples were obtained from animals under light
Nembutal anesthesia (0.1 c,c/gm of a 7 mg./ml. solution of
Nembutal, administered i.p.).

The anesthetized animals were

placed under a warm lamp to dilate their tail vessels, and
a small sample of blood was drawn from a nick in the tail
into a white cell diluting pipette, and diluted 1:20 with
0.1# HCL.

Total white cell counts were done in a standard

counting chamber.

A drop of blood was placed on a glass

slide, smeared, and stained with Wrights stain for deter¬
mination of per cent lymphocytes.

Total lymphocyte counts

were computed.
Skin Grafting
Ventral abdominal and thoracic skin sections, about
1 cm2, were

taken from donor mice and grafted on the

dorsal thoracic wall of recipients, according to the
method of Dillingham (2).

The selection of the respective

sites for removal and placement of skin grafts was deter¬
mined by the need to obtain skin from an area with fewer
variations in hair cycles {Dr. Masao Kanaoka - personal
communication), and to place grafts where the recipients
could not bite or scratch them off.

Plaster casts were

removed on day 6 (this required anesthesia), and the grafts
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were followed daily by visual inspection, until destruc¬
tion was essentially complete
ing).

(10# or less of graft surviv¬

We have not used the same strains as either Monaco

and Russell

(26, 31)3 or Levey and Medawar (20, 21).

However, all of these investigators have noted, in the same
references, that strong histocompatibility differences
between donor and recipient mice were easily overcome by
anti-lymphocyte serum.

Although we have not raised an

anti-lymphocyte serum for control, we feel our grafting
results are comparable to theirs.

Our recipient strain

was chosen because of the availability of a myeloma in
the same strain (C3H), and our donor strain (Balb/c) was
chosen for non-scientific reasons
able at the time).

(these mice were avail¬
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RESULTS
Cytotoxic Antibody Studies
Several attempts at perfecting the technique were
tried,with unsatisfactory results.

Data from these early

experiments will not be presented.
Figure 1 shows an experiment done with the perfected
technique, showing cytotoxic titrations of anti-myeloma
serum (AMS), anti-lymphocyte serum (ALS), and normal rabbit
serum (NRS), against myeloma cells.

The heavy horizontal

line represents the percent dead cells in the initial suspen¬
sion,

Initial and final complement controls were in the

same range.

Clearly, our AMS has a very high cytotoxic

titer against myeloma cells.

Dr, Monaco*s antilymphocyte

serum has significant activity against the same cells, but
clearly the AMS has much more effect at higher dilutions.
Normal rabbit serum has no cytotoxic effects.

Points from

titrations performed with AMS against myeloma cells on two
other occasions are depicted also.

The line is drawn

through the points attained with the same cell sample used
for the single ALS titration,however.
Figure II,depicting an experiment kindly done for us
by Dr, Kikuo Nomoto, demonstrates that AMS has a signifi¬
cant but rather low cytotoxic titer against lymphocytes.
Figure III represents cytotoxic titration of AMS done
in parallel with samples of the same serum absorbed with
lymphocytes (AMS/L), and with myeloma cells (AMS/M).
Cleanly our absorptions were inadequate,

as the absorption

.
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FIGURE I - Cytotoxic activity of AMS, AL3,
and NR3 afainst X5563 myeloma cells

Horizontal line at 35$ = per cent dead cells in
initial cell sample
Initial complement control - 35$ dead cells
Final complement control
- 25$ dead cells
Legend
1M0

o*-o ALS
&— A

URS

The three connected lines represent titrations
done simultaneosly with the same cell sample.
Separate points from AMS titrations done at
two other times are drawn, but not connected.
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FIGURE II - Cytotoxic activity of AMS
against C3H lymph, node cells

% dead cells

l/dil. of antiserum
Complement control - 21 %

.

FIGURE III - Titration of cytotoxic acivity
of AMS, AMS absorbed with lymphocytes
(AMS/a), and AMS absorbed with myeloma
cells (AMS/M) against X5563 myeloma
cells

% dead cells

Horizontal line represents 33^ dead cells in
initial cell sample
Initial complement control - 29% dead cells
Final Complement control
- 31$ dead cells
Legend
—* AMS
0-o AM3/L '

a-a AMS/M
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with myeloma cells should have lowered the curve to the
baseline of % initial dead cells.

It is tempting to con¬

clude that, since the AMS/L curve Is not lowered as far as
the AMS/M curve, there are antigens on the myeloma cell
foreign to the lymphocyte.

This cannot be concluded from

the experiment, however, until we are able to absorb the
serum fully with myeloma cells, and perform equivalent
lymphocyte absorptions.
It is clear, however, that our AMS has a high titer
against X5563 myeloma cells, much higher than that of
Dr. Monaco's very potent ALS, which was prepared identi¬
cally.

Our AMS also has a very low titer against lympho¬

cytes.

These data demonstrate that lymphocytes and myeloma

share some antigenic components.

One might argue also that

they show that each cell type has specific antigens not
shared by the other.

Other factors may be involved in

determining the cytotoxic titer of a serum versus a cell
different from that against which It was raised, than the
degree of antigenic identity of the two cell types one is
dealing with.

We hesitate to conclude with certainty,

then, that lymphocytes and myeloma cells both have antigens
not shared by the other, from this experiment alone.

To be

sure, we will have to perform more complete absorptions of
each serum with both cell types, getting each serum com¬
pletely absorbed with its "own" type of cell, absorb equi¬
valently with the other cell, and see if any activity remain
Gel diffusion studies, not included in this protocol, are
also planned.

.
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Lymphopenia Experiment
Figure IV shows the results of an experiment performed
over 120 hours on 8 C3H mice to determine the lymphopenic
effects of ALS, AMS, and NRS.
serum was given to each animal.

A total of 4 injections of
Two animals received

injections each time of 0.25 c.c. ALS, 0.25 c.c. AMS, and
0.75 c.c. AMS,

One animal got 0.25 c.c. of NRS each time,

and another got 0.75 c.c. of the same.

It is evident that

all sera had a lymphopenic effect 8 hours after the first
injection.

Clearly, ALS had a far more profound effect

at this time than the other sera, and this difference was
maintained throughout the experiment.

Animal #6, given

injections of 0.75 c.c. AMS, had a particularly marked fall
at 8 hours, but to a level twice as high as that in the
animal with the lesser response to ALS.

After 24 hours

the lymphocyte count of animal # 6 returned to the range
of those of NRS recipients, where it stayed.

At 46 hours,

the lymphocyte count of animal # 8, which got 0.25 c.c,
AMS each time, fell within the range of the counts of ALS
recipients (which had risen to this level and subsequently
fell).

However, animal # 8’s lymphocyte count was within

the normal range at all other times.

Animals # 5 and 7,

also recipients of AMS, had lymphocyte counts within the
normal range at all times.

It is quite clear from this

experiment that Dr. Monaco’s ALS, raised against A/Jax
lymphocytes, exerted a profound and persistent depression
over the course of the experiment on the peripheral lympho¬
cyte counts of C3H mice,*

our AMS, however,did not exert
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FIGURE IV - Effect of ALS, AMS, and HRS on
peripheral lymphocyte counts
of 03H mice

1 ympho p y t e s /mm

Hours
(serum injections indicated by arrows)
Legend of serum and doses
given with each injection
o—o 0.25 c.c. aLS

animal
no. :
(1,2)

0.25 c.c. AMS

(7,3)

&—&

0.75 c.c. AMS

(5,6)

A—Jk

0.25 c.c. HRS

(3)
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an effect significantly different from that of MRS, even
though the AMS has a high titer against a cell of C3H
origin which shares antigens with lymphocytes.
Skin

Grafting
Several regimens of AMS treatment were tested for

their effect on the allograft response.

Four groups of

C3H mice received daily i.p. injections, for 7 days, of
0.25 c.c. AMS, and AMS absorbed with myeloma cells, lympho¬
cytes, and C3H serum, respectively.
0)

The following day (day

al mice were grafted with Balb/c skin.

group received similar injections of MRS.
mice received any serum after grafting.

A control
None of these

Another group

received injections of 0.25 c.c. AMS for 7 days prior to
grafting, as well as 0.5 c.c. on days +2

and +6.

Still

another group received daily injections of 0.75 c.c,AMS
for 5 days prior to graftingj 0.5 c.c. on days 0, +1, +2,
and +3; and 0.25 c.c. on days +6 and +7.
received similar injections of NRS.

A control group

A small number of

animals had grossly infected grafts when plaster casts were
removed on day +6, and the recipients of these grafts have
been excluded from the study.

Figure V depicts,day by day,

the number of surviving grafts observed in each group.

The

day on which a graft was observed to be rejected, and
removed from the survival table, was chosen as the numerical
determinant if the number of days the graft survived.

The

mean survival time of grafts in each group has been comput¬
ed and included in Figure V;

it was not felt necessary
>
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to calculate standard deviations.

Clearly none of the

serum regimens prolonged allograft survival significantly,.
In fact, the lower doses of AMS were associated with a
slightly accelerated rejection, if anything.

The sera

absorbed with cells, we have seen, were not effectively
absorbed, and can be considered as AMS,

Injections in the

mice that received the very high serum doses were cut back,
on day +3, because one of the animals in the NRS cage was
obviously cachectic with weight loss, lethargy, and
tachypnea.
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FIGURE V - Effect of various regimens of
AMS and NRS on the rejection of
Balb/c shin grafts by C3H mice

serum
treatment
no serum

no. of grafts surviving per day
post grafting
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AMS/L, AMS/M, AMS/S = AMS absorbed with lymphocytes,
myeloma cells, and C3H serum, respectively
M3T - mean survival time of grafts in each series.
Survival time is defined as the number of the day a graft
was found to be rejected (i.e. the dajr a graft
was removed from the survival table).
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DISCUSSION

We have presented clear evidence that a serum direct¬
ed against a cell of C3H origin, other than the lymphocyte,
has no significant effect on peripheral lymphocyte counts,
and fails to depress the allograft response, when administer¬
ed to C3H mice.

In contrast, a serum prepared by the same

protocol, against the lymphocytes of another strain of
mice (A/Jax), has a profound lymphopenic effect on C3H mice.
Our anti-myeloma serum (AMS) has a high cytotoxic antibody
titer against myeloma cells, and a very low, but signifi¬
cant, titer against lymphocytes.

In contrast. Dr. Monaco’s

ALS has a titer against myeloma cells two tubes lower than
that of AMS.

We did not perform a parallel cytotoxic

titration of ALS against C3H lymphocytes.

This titer can

safely be presumed to be high, however, as Gray et al.

(10)

have shown that the same serum has a leukoagglutionation
titer against G3H lymphocytes comparable to that achieved
against A/Jax lymphocytes, which was high.
Jeejeebhoy (18) has recently objected that cytotoxic
and leukoagglutinin titers, as well as induction of lympho¬
penia, cannot always be correlated with Immunosuppressive
effects of antilymphocyte sera, and that at present no
satisfactory test is available for predicting the immuno¬
suppressive effects of batches of antilymphocyte serum.
He raised serum against rat lymphocytes in both dogs and
rabbits.

He maintained that both sera had comparable

cytotoxic leukoagglutinin activity against rat lymphocytes.
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and, seemed to imply that both sera produced initial lympho¬
penia in rats, although the rabbit serum did so more effect¬
ively;

only the rabbit serum had any immunosuppressive

effects, however.

If these observations are accurate, they

cast considerable doubt on the "cytotoxic" theory, as well
as upon the validity of much of the in vitro work presented
above.

Jeejeebhoy's cytotoxic titers indeed seem to be

similarly high with both sera, but close examination of
his lymphopenia data reveals that, over the course of 4
hours, his dog anti-rat lymphocyte plasma, which had no
immunosuppressive effects, had a lymphopenic effect not
significantly different from that of normal dog plasma.
He did not follow the lymphocyte counts beyond 4 hours. The
point that lymphopenia (in the initial stages of serum
treatment) cannot be correlated with immunosuppressive
potency is not established by this study.

Certainly his

dog sera did have high in vitro titers against rat lympho¬
cytes, however.

It is quite conceivable that some dogs

cannot recognize specific rodent lymphocyte antigens, how¬
ever.

A non-specific dog anti-lymphocyte preparation

might then fix just as easily on many other tissues, or be
eluted easily from lymphocytes onto other tissues.
been shown in the studies of Gray et al.
et al,

It has

(10), and Monaco

(26) that the cytotoxic and lymphagglutinatin

acitivity of their rabbit anti-mouse lymphocyte serum does
correlate with immunosuppression and lymphopenia.

We have

used this animal system in our experiments, and feel we
have achieved a good correlation.
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Further absorption of both sera with both kinds of
cells, followed by gel-diffusion studies or more cytotoxic
titrations, are needed to quantitate fully how much anti¬
genicity is common to lymphocytes and myeloma cells, as
well as other tissues (which were not studied here), and
whether the lymphocyte has specific antigens of its own.
Nevertheless, our experiments suggest quite clearly, but
probably in a qualitative way only, that lymphocytes and
myeloma cells do share some antigens.

Other factors may

be involved, but it is tempting to conclude from our experi¬
ments that both the myeloma cell and the lymphocyte are
capable of raising sera specific for themselves, at least
having significantly higher titers against the immunizing
cell than against other cells, and with, in the case of
ALS, a "clinically" specific in vivo effect.
It is probably not reasonable to expect the lympho¬
cyte to have its entire complement of anitgens cell-speci¬
fic, simply because all cells come from the same fertilized
ovum.

Indeed, Russell and Monaco have observed (31) that

the specificity of ALS may involve the whole array of
individual specific antigens concerned with histocompati¬
bility in allogenic combinations.

It is certainly not

unreasonable to hypothesize that individual cell groups,
r

in particular lymphocytes, might have some antigenic
specificities not present on other cells.

The general

physical availability of lymphocytes, a relative suscepti¬
bility to mechanical lysis (or transformation), or a high
concentration of antigen (either cell or species specific).
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may be contributing factors in the action of ALS.

The

failure of our high titer anti-myeloma serum, which had
some activity against lymphocytes, to depress lymphocyte
counts or prolong graft survival, seems to minimize the
importance of the latter factors, however, as we might
have expected AMS to be at least partially effective if
these mechanisms were critical.

It would seem highly

likely that some degree of cellular antigenic specifi¬
city is involved.

Levey (20) did achieve immunosuppression

with an anti-epidermal cell serum, but less than that
achieved with ALS.

His results are not inconsistent with

our hypothesis.
ALS had been proven to be a powerful immunosuppressive
agent.

The main practical question involved in the issue

of specificity,

it would seem. Is whether absorption with

other tissues might be of value in preparation of sera
for use in vivo.

If indeed lymphocytes possess specific

antigens, one might conceivably expect such absorptions
to lower the toxicity of the serum, and perhaps to increase
its effectiveness per given dose - both effects by decreas¬
ing avidity for non-lymphoid tissues.
Our experiments have been directed at the specificity
of anti-lymphocyte serum and other sera for the lymphocyte.
We do not offer evidence in favor of either the ''cytotoxic”
or "sterile activation" theories of the manner of action
of ALS.

Indeed, both theories probably depend on the

specificity of ALS for the lymphocyte.
The possibilities for the clinical use of antilymphocyte
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serum in organ transplantation seem excellent.

Hopefully

our experiments will contribute to the quantitation of
the degree of immunological specificity this serum has
for the lymphocytej and to understanding of the relevance
of such specificity to the immunosuppressive action of the
serum.
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SUMMARY

The current literature pertaining to the specificity
and mode of action of antilymphocyte serum as an immuno¬
suppressive agent has been critically reviewed.

Experi¬

ments are described in which a serum is raised against
a mouse (C3H strain) transplantable myeloma.

This serum

has a high cytotoxic antibody titer against myeloma cells,
and a lower, but significant, titer against C3H lymphocytes.
In contrast, a potent known antilymphocyte serum, prepared
by the same protocol, has a relatively lower cytotoxic
titer against myeloma cells,*

this same serum has been

shown by others to have high agglutination activity against
C3H lymphocytes.

Anti-myeloma serum did not have an

effect on the lymphocyte counts of C3H mice significantly
different from that of normal mouse serum, whereas anti¬
lymphocyte serum profoundly lowered peripheral lympho¬
cyte counts.

Finally, antimyeloma serum had no effect on

the allograft response in any doses, both pre- and post¬
graft.
cussed .

Possible significance of these findings is dis¬

-

-

page 39

Acknowledgments
I am most grateful to Dr. Paul S. Russell for extend¬
ing the opportunity to work as a research assistant in his
laboratory at the Massachusetts General Hospital during
the summer of 1966;
project was born.

from that experience the idea of this
Thanks are also due to Dr. Russell for

offering the facilities of his laboratory for the beginning
of this work, during October 1967, after I had finished a
clinical clerkship on his surgical services.

Unfortunately,

1

I did not get a chance to get much done then, since I had
to return to Yale earlier than expected, and, I must admit,
because the Red Sox were in the World Series and I had
tickets.
I am very much indebted to Dr. Anthony P. Monaco for
his kind donation of a sample of his anti-lymphocyte serum,
which proved most valuable in this study.
Thanks are also due to Dr. Samuel Nelson for suggest¬
ing the use of myeloma cells, to Dr. Kikuo Nomoto for his
help with the cytotoxic antibody titrations, and to
Dr. Stanley Order for his advice and encouragement.
Last, but only as a fitting way to finish, I express
my profound thanks to Dr. Byron H. Waksman, who served as
faculty advisor for this thesis, for his unfailing advice,
eminently constructive criticisms, and his sustaining
good nature.

.

i

:

i.

.

n /x'ii <

.

.

.

dv .■

I

' 5

Iu6-

..

.f.

tUtaOW elrf;? lo

.
.

,

ri

.(:

nr>

f.-

•

■

c;

r«■

.

,

.

oj

L L■

. €d

y;Ino Jxi:[

,

• y. -r? t »c

page 40

BIBLIOGRAPHY
1. )

Anderson, N.F., James, K,, Woodruff, M.F.A. 1967. Effect
of anti-lymphocytic antibody and antibody fragments
on skin homograft survival and blood lymphocyte
counts in rats.
Lancet, 1:1126

2. )

Billingham, R.E. 1961.
Free skin grafting in mammals.
In:
Transplantation of Tissues and Cells, 1961,
By R.E. Billingham and W.K, Silvers, pp.i-23,
Wistar Institute Press, Philadelphia

3. )

Boyse, E.A., Old, L.J., and Thomas, G.
A report on
some observations with a simplified cytotoxic
test. Transpi. Bull. 29:635 1962

4. )

Boyse, E.A., Old, L.J., and Chouroulinkov, I. 1964.
A cytotoxic test for demonstration of mouse
antibody,
Meth. Med. Res. 10:39-47.

5. )

Cerilli, J,, Groth, C,, Taylor, P., and Daloze, P.
1967.
The effect of donor treatment with homolo¬
gous antilymphocyte globulin in kidney homograft
survival,
Transpi. 5•1334

6. )

Chew, W.B., and Lawrence, J. 1937.
serum,
J, Immunol. 33s271.

7. )

Cruickshank, A.H. 1941. Antilymphocyte serum, Brit,
J, Exp, Path. 22;121

8. )

Gordon, B.L,, 2nd, Fong, J., and Papermaster, B.W,
1967. Purification without loss of viability of
neoplastic plasma cells from ascites passaged
mouse myeloma X5563*
Blood 29 suppl,:647

9. )

Grasbeck, R., Norman, C., and Be la Chapelle, A. 1964,
The leukocyte mitogenic effect of serum from
rabbits immunized with human leukocytes.
Acta
Med. Scand. Suppl. 412:39

Antilymphocyte

10. ) Gray, J.G., Monaco, A.P., Wood, M.L., and Russell, P.S.
1966.
Studies on heterologous anti-lymphocyte
serum in mice.
I. In vitro and In vivo properties,
J. Immunol. 96:217
11. ) Guttman, R.D., Carpenter, C.B., Lindquist, R.R.,and
Merrill, J.P. 1967.
An immunosuppressive site
of action of heterologous antilymphocyte serum.
Lancet, 1:248
12. ) Interbitzin, T. 1956.
The relation of lymphocytes,
delayed cutaneous allergic reaction, and histamine.
Int. Arch. Allergy.
8:150

*

.

.

£

t X< • £

:

.".'

.

.

.
X

'■

.

c

.

•

.

(,S

.

.

,
,

.

t

. T7£ c. )

(.X
"CO r

.

,

C'- X3':::
( •t

■

t.
.

,.

.

....

. : i. :
■

'■

. ••■jo

;
, n£XIJtH
‘..T
:nl
„S,K

-

• [

. . £:

,

:

.

. .1

./:£..
.

i

,

. .
■: o'..

•

.

.

. ,

. . .
.
..
sucni ' o no.^^osno- sc
■<: • :

'

,
. .
xioXtodnaXc

>. 0 Ins E.r’iJi:3.*:T
. . 1

xo

(,X

......

. Xociuffifetl .1.
.

'

.

,

[

£'. I:.

,

. .

. ric

•

. c:.. . £.
. . I.

.

.

•.

.

.

. ■

ml

{
:

.

.1

■

.

’

...

,

u

'

: I: :
.

.

r'

.
: <■:

.

.£

■

X

c■

(.€

...

.

.

' :i.:

-

.OX

.
,

;

.
I.

i nc

♦

V *

4-.,*.r

. • £ ■

£

. .

.

. '

..

t r - .,
^

, uttl

page 4l

13. )

Iwasaki, Y., Porter, K., Amond, J.R., Marchiori, T.L.,
Zuhlke, V., and Starzl, T.E. 1967.
Preparing and
testing of horse anti-dog and anti-human antilympho¬
cyte plasma or serum and its protein fractions.
Surgery, Gynecology, and Obstetrics. 124:1

14. )

James, K. 1967.
Some factors influencing the ability
of anti-lymphocyte antibody to suppress humoral
antibody formation.
Clin, Exp.
Immunol. 2:685

15. )

James, K. 1967*
Anti-lymphocyte antibody - a review,
Clin. Exp. Immunol. 2:615

16. )

James, K., Anderson, N.F. 1967. Effect of anti-lympho¬
cyte antibody on humoral antibody formation.
Nature (London) 213:1195

17. )

James, K. and Medawar, P.B. 1967. Characterization of
anti-lymphocyte antibody.
Nature (London) 214:1025

18. )

Jeejeebhoy, H.F. 1967.
The relation of lymphopenia
production and lymphocyte agglutinatin and cyto¬
toxic antibody titers to the immunosuppressive
potency of heterologous anti-lymphocyte plasma,
Transpl. 5?1121

19. )

Lance, E.M., and Dresser, D.W. 1967.
Antigenicity in
mice of anti-lymphocyte gamma globulin.
Nature
(London) 215:488

20. )

Levey, R.H., and Medawar, P.B. 1966.
Nature and mode
of action of antilymphocytic antiserum.
Proc.
Nat. Acad. Sci.
56:1130

21. )

Levey, R.H., and Medawar, P.B. 1966,
Some experiments
on the action of antilymphoid antisera.
Ann. N.Y.
Acad. Sci. 129:164

22. )

Levey, R.H., and Medawar, P.B. 1966.
Mechanism of
action of antilymphocyte serum.
Surg. Forum.
17:247

23. )

Levey, R.H., and Medawar, P.B. 1967.
The mode of
action of antilymphocytic serum.
In:
Ciba Study
Group # 29 - Antilymphocytic Serum, pp. 72-80,
ed. by G.E.W. Wolstenholme and M. O’Connor.
Little,
Brown, Boston.

24. )

Ling, N.R., Knight, S., Hardy, D., Stanworth, D.R., and
Holt, P.J.L. 1967.
Antibody induced lymphocyte
transformation in vitro. 1967.
In:
same ref. as
# 23, pp. 41-50,

25. )

Monaco, A.P., Abbott, W.M., Otherson, H.B., Simons,R.L.,
Wood, M.L., Flax, M.H., and Russell, P.S. 1966.

.

.

.

.

; n‘
:

'

. .

.. <

.

.

.

.'

. ftSrtas'O

( »#1

*

.

:

.

.

. -C r.» <:.? ■ ■

.

.

. <

' i )

.
.

.

,

'

.

.

.

.

IS II:
.

\'

«Xcrsit
,..

Da fid

,,..

:

.

,e .

t. K . H
■ X;

.

: .

,

.
Tt'SsTX
li

, '3 i>>

•

\

V •

.

V.-

.
\

^niOT.c

0

J

.
l '•1

1 '

V

•

l

hoc

;

. 0

’., V

t; o

-

,

•

' 1

.

page 42

antiserum to lymphocytes: prolonged survival of'
canine renal allografts.
Science, 153*1264
26. )

Monaco, A.P., Wood, M.L., Gray, J.G., and Russell, P.S.,
1966.
Studies of heterologous anti-lymphocyte
serum in mice.
II: Effect on the immune response.
J.
Immunol, 96:229

27. )

McGregor, D.D., and Gowans, J.L. 1963.
Antibody
response of rats depleted of lymphocytes by chronic
drainage from the thoracic duct/ J. Exp. Med,
117:303

28. )

McGregor, D.D., Gowans, J.L, 1964,
Survival of homo¬
grafts of skin in rats depleted of lymphocytes by
chronic drainage from the thoracic duct. Lancet,
1:629

29. )

Nagaya, H,, and Sieker, H, 0. i960.
Allograft survi¬
val:
effect of antisera to thymus glands and
lymphocytes.
Science, 150:1181

30. )

Nagaya, H,, and Sieker, H.O., 1966.
Lymphopenic
effect of antilymphocyte serum,
Proc. Soc, Exp,
Biol. Med, 121:722

31. )

Russell, P.S„, and Monaco, A.P. 1967.
Heterologous
antilymphocyte sera and some of their effects.
Transpl. 5*1086

32. )

Sacks, J.H., Fillipone, D.R., and Hume, D.M, 1964.
Studies on immune destruction of lymphoid tissue,
I:
Lymphocytetoxic effects of rabbit anti-rat
lymphocyte antiserum.
Transpl. 2:60

33. )

Starzl, T.E., Marchioro, T.L., Porter, K.A., Iwasaki,
Y., and Cerilli, G.J. 1967.
Use of heterologous
antilymphocyte agents in canine renal and liver
homotransplantation and in human renal homotransplantation.
Surg,, Gyn., and Obst., 124:301

34. )

Waksman, B.H., Arbouys, S,, and Arnasonf| B.O. 1961,
Use of specific "lymphocyte antisera 1 to inhibit
hypersensitive reactions of the delayed type.
J. Exp. Med. 114:997

35. )

Starzl, T.E., Porter, K.A., Iwasaki, Y., Marchioro,
T.L,, Kashiway, N. 1967.
The use of heterologous
antilymphocyte globulin in human renal homotrans¬
plantation.
In:
Ciba Study Group #29: Antilymphocytic Serum, (ed. by G.E.W, Wolstenholm and M.
O’Connor)
Little, Brown; Boston pp. 4-34

36. )

Wilhelm, R.E., and Fisher, J.P. 1961. Experimental
depletion of mononuclear cells for the purpose of

r

.

.

.

: v.

■:

.

.

.o

u

I

...

"* ■

' .■

:: ■

.

■:

v •*
■

'

i -

■

;

‘

..

,

.

.

.

•

m.i

• . ,

.
'

»

■ X ;

\ ■ ,

-to:

.

.

.

:
I

.

. .

.

' r:

. .

.'

. .

.

■

,

-

,

.

t

'! ■ 1

i

■

, ;. '■

.

'

.1- : '

. ':S.Zx-'

( .S£

,

. :t: '

,2

.

.

:
'<>P

• i' ’ r

visti

.
, to
)
.

•'

*

-

page 43

investigating reaction of the delayed contact type.
J. Allergy, 29:493
37. )

Woodruff, M.F.A. i960. The Transplantation of Tissues
and Organs.
Chas. C. Thomas, Springfield, Ill.

38. )

Woodruff, M.F.A., and Anderson, N.F. 1963. Effect of
lymphocyte depletion by thoracic duct fistula'and administration of anti-lymphocyte serum on survival
of skin homografts in rats.
Nature (London) 200:
703

39*)

Woodruff, M.F.A., Anderson, N.F, 1964. (same title as
# 37)
Ann. N.Y. Acad. Sci. 120:119

40. )

Woodruff, M.F.A., Anderson, N.F., and Abaza, H.M.
1966. Experiments with antilymphocyte serum.
In:
Bristol Symposium; The Lymphocyte and
Hematopoiesis, ed. by J.M. Yoffey, pp. 286-291.
Edward Arnold, London.

41. )

Woodruff, M.F.A., Reid, B.L., and James, K.
1967.
The effect of anti-lymphocyte antibody and anti¬
body fragments on human lymphocytes in vitro.
Nature (London) 215:591

42. )

Woodruff, M.F.A., James, K., Anderson, N.F,, and Reid,
B.L. 1967.
Comparison of in vitro and in vivo
properties of antilymphocyte serum.
In: Ciba
Study Group #29 - Antilymphocytic serum, pp. 57“
68, ed, by G.E.W. Wolstenholme and M, O’Connor.
Little, Brown, Boston

UA

■

.

.

...

.

’ .

...

'xx.iJ i '

.7.

. ad .-s'x nJ:

iuT&ooW

3 ^.goroii r<1 •

".c

(

■
.

>

•

*

0/'

,

,

-

.

.„ y.

,

,
.

i nl
.

.

-V

.

,

-

.

■jVQO
. .

■

nl ye"0

....
0

•

.

.

.

.
, t;
. .

(,8C

• r

;.o\

.
r • -f $• "

•

YALE MEDICAL LIBRARY
Manuscript Theses

Unpublished theses submitted for the Master's and Doctor's degrees and
deposited in the Yale Medical Library are to be used only with due regard to the
rights of the authors.

Bibliographical references may be noted, but passages

must not be copied without permission of the authors, and without proper credit
being given in subsequent written or published work.
This thesis by

has been

used by the following persons, whose signatures attest their acceptance of the
above restrictions.

NAME AND ADDRESS

DATE

